Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

SIMPLE SUMMARY: Second line anti-PD1 immunotherapy is effective in selected BRAF-mutated melanoma patients after BRAFi/MEKi immunotherapy failure. Nivolumab and pembrolizumab are of similar efficacy as a second line therapy. Worse performance status as well as high LDH levels are negative clinical b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogala, Paweł, Czarnecka, Anna M., Cybulska-Stopa, Bożena, Ostaszewski, Krzysztof, Piejko, Karolina, Ziętek, Marcin, Dziura, Robert, Rutkowska, Ewa, Galus, Łukasz, Kempa-Kamińska, Natasza, Seredyńska, Joanna, Bal, Wiesław, Kozak, Katarzyna, Surus-Hyla, Anna, Kubiatowski, Tomasz, Kamińska-Winciorek, Grażyna, Suwiński, Rafał, Mackiewicz, Jacek, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101360/
https://www.ncbi.nlm.nih.gov/pubmed/35565255
http://dx.doi.org/10.3390/cancers14092123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101360/
https://www.ncbi.nlm.nih.gov/pubmed/35565255
http://dx.doi.org/10.3390/cancers14092123

Ejemplares similares